PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Instituto de Salud Pública de Navarra, Pamplona, Spain.\', \'CIBER Epidemiología y Salud Pública (CIBERESP), Spain.\', \'Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.\', \'Clinical Microbiology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.\', \'Other members of the Working Group for the Study of COVID-19 in Navarre are listed in the Investigators tab.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.2807/1560-7917.ES.2021.26.39.2100894
?:doi
?:hasPublicationType
?:journal
  • Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
is ?:pmid of
?:pmid
?:pmid
  • 34596016
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34596016>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34596016>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all